Study on the Slow-Release Mometasone Furoate Injection of PLGA for the Treatment of Knee Arthritis

Author(s): Yutong Liang, Jiaojiao Zhang, Xinghua Zhao, Ming Wang, Shi Ding, Yang Wang, Ye Chen*, Ju Liu*

Journal Name: Current Drug Delivery

Volume 18 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Purpose: The purpose of this study is to develop a new PLGA based formulation for microspheres, which aims to release mometasone furoate for one month, so as to improve compliance.

Methods: The microspheres containing mometasone furoate were prepared by oil in water emulsion and solvent evaporation. The microspheres were characterized by surface morphology, shape, size and encapsulation efficiency. The release in vitro was studied in 37°C phosphate buffer, and in vivo, pharmacodynamics and preliminary safety evaluation were conducted in male Sprague Dawley rats.

Results: The morphology results showed that the microspheres have a smooth surface, spherical shape and an average diameter of 2.320-5.679μm. The encapsulation efficiency of the microspheres loaded with mometasone furoate was in the range of 53.1% to 95.2%, and the encapsulation efficiency of the microspheres could be greatly affected by the proportion of oil phase to the water phase and other formulation parameters. In vitro release kinetics revealed that drug release from microspheres was through non-Fick's diffusion and PLGA polymer erosion. Pharmacokinetic data showed that the initial release of microspheres was small and then sustained. The results of the pharmacodynamics study fully proved the long-term effectiveness of mometasone furoate microspheres. The results of in vivo safety evaluation showed that the preparation system possessed good in vivo safety.

Conclusion: This study shows that the microspheres prepared in this study have sufficient ability to stable drug release at least for 35 days, with good efficacy and high safety. In addition, mometasone furoate can be used as a potential candidate drug for 35 days long-term injection.

Keywords: Osteoarthritis, mometasone furoate, compliance, solvent evaporation, long-acting injections, biodegradable polymer.

[1]
Boers, M. Glucocorticoids for rheumatoid arthritis in the era of targeted therapies. Reumatol. Clin., 2019, 15(6), 311-314.
[http://dx.doi.org/10.1016/j.reuma.2019.05.003] [PMID: 31239208]
[2]
Lu, Y.C.; Evans, C.H.; Grodzinsky, A.J. Effects of short-term glucocorticoid treatment on changes in cartilage matrix degradation and chondrocyte gene expression induced by mechanical injury and inflammatory cytokines. Arthritis Res. Ther., 2011, 13(5), R142.
[http://dx.doi.org/10.1186/ar3456] [PMID: 21888631]
[3]
Guo, M.; Liu, H.; Ji, K.; Xiong, K. advances in local administration preparations of triamcinolone acetonide. China Pharmacist, 2016, 19(03), 559-562.
[4]
Zhang, J.; Liu, H. PLGA Preparation of sustained-release microspheres and their sustained-release properties. Chin. J. Clin. Rational Drug Use, 2019, 12(01), 174-175.
[5]
Farshad, R.; Weiluan, C.; Cornelis, F. van Nostrum.; Gert, S.; Fabian, K.; Twan, L.; Wim E.; Hennink; Robbert J.; Kok. Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: state-of-the-art and challenges. Int. J. Pharm., 2016, 499(1-2), 358-367.
[6]
Rudnik-Jansen, I.; Schrijver, K.; Woike, N.; Tellegen, A.; Versteeg, S.; Emans, P.; Mihov, G.; Thies, J.; Eijkelkamp, N.; Tryfonidou, M.; Creemers, L. Intra-articular injection of triamcinolone acetonide releasing biomaterial microspheres inhibits pain and inflammation in an acute arthritis model. Drug Deliv., 2019, 26(1), 226-236.
[http://dx.doi.org/10.1080/10717544.2019.1568625] [PMID: 30843733]
[7]
Qiu, X.; Zhen, P.; Li, S. Current advances in the drug-loading preparation of poly (lactic-co-glycolic acid) microspheres. Chin. J. Tissue Engr. Res., 2018, 22(10), 1599-1604.
[8]
Rudnik-Jansen, I.; Colen, S.; Berard, J.; Plomp, S.; Que, I.; van Rijen, M.; Woike, N.; Egas, A.; van Osch, G.; van Maarseveen, E.; Messier, K.; Chan, A.; Thies, J.; Creemers, L. Prolonged inhibition of inflammation in osteoarthritis by triamcinolone acetonide released from a polyester amide microsphere platform. J. Controlled Release Soc., 2017, pp. 253.
[9]
Shi, Y.; Li, H.; Xu, M.; Li, Y.; Zhang, N.; Huang, G.H. Orthogonal experiments for optimizing the formulation and preparation conditions of tetramethylpyrazine loaded PLGA microspheres. Shandong Daxue Xuebao. Yixue Ban, 2010, 48(01), 154-158.
[10]
Li, Z. Study of poly(lactic-co-glycolic acid) microspheres containing dexamethasone acetate for intra-articular injection. PLA Acad. Military Med. Sci., 2004, 289(1-2), 63-67.
[11]
Bodmeier, R.; Mcginity, J.W. Solvent selection in the preparation of poly(D,L-lactide) microspheres prepared by the solvent evaporation method. Int. J. Pharm., 1988, 43, 179-186.
[12]
Cao, Y. Determination of the related substances in mometasone furoate cream by HPLC. Anhui NHU Pharmaceut. Com. Ltd., 2016, 20(05), 870-873.
[13]
Chen, J.; Jiang, X. Determination of the content of the nasal spray of amitasone furfurate nasal spray by HPLC. Zhongguo Xin Yao Zazhi, 2004, (02), 144-146.
[14]
Li, J.; Wang, N.; Wu, X. A novel biodegradable system based on gelatin nanoparticles peptide drug and poly(lactic-co-glycolic-acid)-microspheres for protein and delivery. J. Pharm. Sci., 1997, 86(8), 891-895.
[http://dx.doi.org/10.1021/js970084i] [PMID: 9269865]
[15]
Cohn, D.; Younes, H. Compositional and structural analysis of PELA biodegradable block copolymers degrading under in vitro conditions. Biomaterials, 1989, 10(7), 466-474.
[http://dx.doi.org/10.1016/0142-9612(89)90088-4] [PMID: 2804234]
[16]
Johansen, P.; Men, Y.; Merkle, H.P.; Gander, B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm., 2000, 50(1), 129-146.
[http://dx.doi.org/10.1016/S0939-6411(00)00079-5] [PMID: 10840197]
[17]
Zhang, Y.; Huo, M.; Zhou, J.; Zou, A.; Li, W.; Yao, C.; Xie, S. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J., 2010, 12(3), 263-271.
[http://dx.doi.org/10.1208/s12248-010-9185-1] [PMID: 20373062]
[18]
Suzuki, M.; Ishigaki, M. Intra-articular preparation for the treatment of arthropathy. US Patent, 2002, 6, 428-804.
[19]
Liang, L.S.; Wong, W.; Burt, H.M. Pharmacokinetic study of methotrexate following intra-articular injection of methotrexate loaded poly(L-lactic acid) microspheres in rabbits. J. Pharm. Sci., 2005, 94(6), 1204-1215.
[http://dx.doi.org/10.1002/jps.20341] [PMID: 15858840]
[20]
Pomonis, J.D.; Boulet, J.M.; Gottshall, S.L.; Phillips, S.; Sellers, R.; Bunton, T.; Walker, K. Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain, 2005, 114(3), 339-346.
[http://dx.doi.org/10.1016/j.pain.2004.11.008] [PMID: 15777859]
[21]
Huang, G. Studies on the intra-articular injectable tetramethyl pyrazinem loaded sustained release PLGA microspheres; The Shandong University: Jinan, 2010.
[22]
Hickey, T.; Kreutzer, D.; Burgess, D.J.; Moussy, F. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials, 2002, 23(7), 1649-1656.
[http://dx.doi.org/10.1016/S0142-9612(01)00291-5] [PMID: 11922468]
[23]
Khang, G.; Lee, J.H.; Lee, J.W.; Cho, J.C.; Lee, H.B. Preparation and characterization of poly (lactide-co-glycolide) micro-spheres for the sustained release of AZT. Korea Polym. J., 2000, 8, 80-88.
[24]
Choi, H.S.; Seo, S.A.; Khang, G.; Rhee, J.M.; Lee, H.B. Preparation and characterization of fentanyl-loaded PLGA microspheres: in vitro release profiles. Int. J. Pharm., 2002, 234(1-2), 195-203.
[http://dx.doi.org/10.1016/S0378-5173(01)00968-1] [PMID: 11839450]
[25]
Wang, Y.; Burgess, D.J. Microsphere technologies. Wright, D.J.B. Long Acting Inject. Implants; Jeremy, C., Ed.; Springer: London, 2012, pp. 167-194.
[http://dx.doi.org/10.1007/978-1-4614-0554-2_10]
[26]
Ratcliffe, J.H.; Hunneyball, I.M.; Smith, A.; Wilson, C.G.; Davis, S.S. Preparation and evaluation of biodegradable polymeric systems for the intra-articular delivery of drugs. J. Pharm. Pharmacol., 1984, 36(7), 431-436.
[http://dx.doi.org/10.1111/j.2042-7158.1984.tb04419.x] [PMID: 6146685]
[27]
Røshol, H.; Skrede, K.K. AErø, C.E.; Wiik, P. Dexamethasone and methylprednisolone affect rat peritoneal phagocyte chemiluminescence after administration in vivo. Eur. J. Pharmacol., 1995, 286(1), 9-17.
[http://dx.doi.org/10.1016/0014-2999(95)00430-S] [PMID: 8566155]
[28]
Ahsan, F.; Rivas, I.P.; Khan, M.A.; Torres Suarez, A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control. Release, 2002, 79(1-3), 29-40.
[http://dx.doi.org/10.1016/S0168-3659(01)00549-1] [PMID: 11853916]
[29]
Tunçay, M.; Caliş, S.; Kaş, H.S.; Ercan, M.T.; Peksoy, I.; Hincal, A.A. Diclofenac sodium incorporated PLGA (50:50) microspheres: formulation considerations and in vitro/in vivo evaluation. Int. J. Pharm., 2000, 195(1-2), 179-188.
[http://dx.doi.org/10.1016/S0378-5173(99)00394-4] [PMID: 10675695]
[30]
Yamamoto, N.; Fukai, F.; Ohshima, H. Dependence of the phagocytic uptake of polystyrene microspheres by differentiated HL60 upon the size and surface properties of the microspheres. Colloids Surf. B Biointerfaces, 2002, 25, 157-162.
[http://dx.doi.org/10.1016/S0927-7765(01)00306-X]
[31]
Su, Z.; Sun, F.; Shi, Y.; Jiang, C.; Meng, Q.; Teng, L.; Li, Y. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D,L-lactide-co-glycolide) microsphere. Chem. Pharm. Bull. (Tokyo), 2009, 57(11), 1251-1256.
[http://dx.doi.org/10.1248/cpb.57.1251] [PMID: 19881277]
[32]
Mulye, N.V.; Turco, S.J. A simple model,based on first order kinetics to explain release of highly water soluble, drugs from porous dicalcium phosphate dehydrate matrices. Drug Dev. Ind. Pharm., 1995, 21, 943-953.
[http://dx.doi.org/10.3109/03639049509026658]
[33]
Higuchi, T. Rate of release of medicaments from ointment bases containing drugs in suspension. J. Pharm. Sci., 1961, 50, 874-875.
[http://dx.doi.org/10.1002/jps.2600501018] [PMID: 13907269]
[34]
John, W.S.; Martin, V.M.; Cynthia, N. Qualitative evaluation of the mechanism of release of matrix sustained release dosage forms by measurement of polymer release. J. Control. Release, 1993, 27, 227-245.
[http://dx.doi.org/10.1016/0168-3659(93)90154-W]
[35]
Yang, Y.Y.; Chia, H.H.; Chung, T.S. Effect of preparation temperature on the characteristics and release profiles of PLGA microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. J. Control. Release, 2000, 69(1), 81-96.
[http://dx.doi.org/10.1016/S0168-3659(00)00291-1] [PMID: 11018548]
[36]
Mogi, T.; Ohtake, N.; Yoshida, M. Sustained release of 17 pestradiol from poly(lactide-glycolide) microspheres in vitro and in vivo . Colloids Surf. B Biointerfaces, 2000, 17, 153.
[http://dx.doi.org/10.1016/S0927-7765(99)00105-8]
[37]
Peppas, N.A. Analysis of Fickian and non-Fickian drug release from polymers. Pharm. Acta Helv., 1985, 60(4), 110-111.
[PMID: 4011621]
[38]
Ratcliffe, J.H.; Hunneyball, I.M.; Wilson, C.G.; Smith, A.; Davis, S.S. Albumin microspheres for intra-articular drug delivery: investigation of their retention in normal and arthritic knee joints of rabbits. J. Pharm. Pharmacol., 1987, 39(4), 290-295.
[http://dx.doi.org/10.1111/j.2042-7158.1987.tb06268.x] [PMID: 2884293]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 3
Year: 2021
Published on: 17 September, 2020
Page: [357 - 368]
Pages: 12
DOI: 10.2174/1567201817666200917124759
Price: $65

Article Metrics

PDF: 17
HTML: 1